Ambrilia Biopharma Inc. Presents Data on its Novel HIV Integrase Inhibitors at the XVI International HIV Drug Resistance Workshop

MONTREAL, QUEBEC--(MARKET WIRE)--Jun 13, 2007 -- Ambrilia Biopharma Inc. (Toronto:AMB.TO - News), a biopharmaceutical company developing small molecules and peptides to treat infectious diseases and cancer, presented preclinical data on its novel series of HIV integrase inhibitors, showing their potential distinct mechanism of action, which may lead to a different resistance profile from known integrase inhibitors currently in clinical development. The abstract entitled "Novel Small Molecule Inhibitors of HIV-1 Integrase" was presented during a poster session at the XVI International HIV Drug Resistance Workshop in Barbados (June 12-16).